Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Janone Inc (JAN)

Janone Inc (JAN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,210
  • Shares Outstanding, K 8,594
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,810 K
  • 60-Month Beta 2.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade JAN with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.30 +96.30%
on 04/05/24
5.08 -11.12%
on 04/23/24
+1.92 (+74.32%)
since 03/22/24
3-Month
0.50 +803.00%
on 01/30/24
5.08 -11.12%
on 04/23/24
+4.01 (+799.58%)
since 01/23/24
52-Week
0.22 +1,948.55%
on 10/10/23
5.08 -11.12%
on 04/23/24
+3.46 (+330.00%)
since 04/21/23

Most Recent Stories

More News
JanOne to Present at the Dawson James 8th Annual Investment Conference

/PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of...

JAN : 4.51 (+4.27%)
JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference

/PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of...

JAN : 4.51 (+4.27%)
JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

/PRNewswire/ -- JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has...

JAN : 4.51 (+4.27%)
JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting

/PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of...

JAN : 4.51 (+4.27%)
JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules

/PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for...

JAN : 4.51 (+4.27%)
JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules

/PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for...

JAN : 4.51 (+4.27%)
JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting

/PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of...

JAN : 4.51 (+4.27%)
JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain

/PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a biopharmaceutical company that is developing multiple drugs to treat chronic diseases like Peripheral Artery...

JAN : 4.51 (+4.27%)
JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023

/PRNewswire/ -- JanOne (Nasdaq: JAN), Dr. Amol Soin, Chief Medical Officer of JanOne, will be presenting at the Appalachian Region Spine and Pain Meeting in...

JAN : 4.51 (+4.27%)
JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team

/PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of...

JAN : 4.51 (+4.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

JanOne is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications....

See More

Key Turning Points

3rd Resistance Point 5.74
2nd Resistance Point 5.41
1st Resistance Point 4.96
Last Price 4.51
1st Support Level 4.18
2nd Support Level 3.85
3rd Support Level 3.40

See More

52-Week High 5.08
Last Price 4.51
Fibonacci 61.8% 3.22
Fibonacci 50% 2.65
Fibonacci 38.2% 2.08
52-Week Low 0.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar